收稿日期: 2019-09-29
网络出版日期: 2021-10-11
基金资助
国家自然科学基金(81730030)
Efficacy and safety of Nocardia rubra cell wall skeleton for the treatment of erosive oral lichen planus
Received date: 2019-09-29
Online published: 2021-10-11
Supported by
National Natural Science Foundation of China(81730030)
目的: 初步观察红色诺卡氏菌细胞壁骨架(Nocardia rubra cell wall skeleton,Nr-CWS)治疗糜烂型口腔扁平苔藓(erosive oral lichen planus,EOLP)的疗效及安全性。方法: 选择60例经临床及组织病理确诊为EOLP的患者,根据随机号随机分入两组,试验组局部使用含Nr-CWS的冻干粉,配合使用生理盐水,对照组局部使用安慰剂(不含Nr-CWS的冻干粉), 配合使用生理盐水。分别于初诊以及用药后第1、2、4周复查时记录患者糜烂病损面积大小和疼痛程度的变化,比较治疗前后患者REU量表(reticulation, erythema, ulceration)、视觉模拟量表以及口腔健康影响程度量表(oral health impact profile, OHIP-14)(中文版)评分的差异,并观察初诊和治疗4周后的安全性指标。结果: 共纳入EOLP患者62例,其中2例失访,试验组31例,对照组29例,平均年龄分别为(52.9±12.4)岁和(54.07±12.40)岁,两组患者的一般情况及口腔卫生状况差异无统计学意义(P>0.05)。试验组患者在治疗后第1、2、4周口腔扁平苔藓的充血糜烂面积明显缩小(P<0.05),缩小率为81.75%,患者的疼痛指数明显降低(P<0.05),口腔健康影响程度计分明显降低(P<0.05),与对照组相比差异有统计学意义(P<0.05),安全性指标与对照组相比差异无统计学意义。结论: Nr-CWS治疗EOLP具有良好的疗效和安全性。
朱正达 , 高岩 , 何汶秀 , 方鑫 , 刘洋 , 魏攀 , 闫志敏 , 华红 . 红色诺卡氏菌细胞壁骨架治疗糜烂型口腔扁平苔藓的疗效及安全性[J]. 北京大学学报（医学版）, 2021 , 53(5) : 964 -969 . DOI: 10.19723/j.issn.1671-167X.2021.05.026
Objective: To observe the efficacy and safety of Nocardia rubra cell wall skeleton (Nr-CWS) for the treatment of erosive oral lichen planus (EOLP). Methods: Sixty patients with clinically and pathologically diagnosed EOLP were randomly divided into the experimental group and control group according to the random number. Patients in the experimental group were treated with lyophilized powder containing Nr-CWS combined with normal saline. Patients in the control group received topical placebo without Nr-CWS combined with normal saline. Changes in the EOLP lesion area and the patient’s pain level were recorded at the timepoints of weeks 1, 2, and 4 after the two different treatments, respectively. The changes of the patient’s REU scoring system (reticulation, erythema, ulceration), the visual analogue scale and the oral health impact score (OHIP-14) were compared between the experimental group and control group after treatment, and the safety indicators of the two groups at the initial diagnosis and after 4 weeks’ treatment were also observed, respectively. Results: Totally, 62 patients with clinically and pathologically diagnosed EOLP were enrolled, 2 of whom were lost to the follow-up, with 31 in the experimental group, and 29 in the control group. The mean age of the experimental group and control group were (52.9±12.4) years and (54.07±12.40) years, respectively. There was no significant difference in the oral periodontal index between the experimental group and control group. In the experimental group, the erosive area of oral lichen planus was significantly reduced 1, 2, and 4 weeks after the Nr-CWS’s treatment (P<0.05), the reduction rate was 81.75%, the patient’s pain index was also decreased (P<0.05), and in addition, the OHIP-14 was reduced (P<0.05). The changes of the REU scoring system, the visual analogue scale and the OHIP-14 were significantly different between the experimental group and control group after treatment. There was no significant difference in the safety index between the two groups. Conclusion: The priliminary data show that the Nr-CWS is effective and safe to treat EOLP.
Key words： Nocardia rubra; Cell wall skeleton; Oral lichen planus; Treatment outcome; Safety
| [1] | 华红, 刘宏伟. 口腔黏膜病学 [M]. 北京: 北京大学医学出版社, 2014. |
| [2] | 陈谦明. 口腔黏膜病学 [M]. 北京: 人民卫生出版社, 2012. |
| [3] | Olson MA, Rogers RS 3rd, Bruce AJ. Oral lichen planus [J]. Clin Dermatol, 2016, 34(4):495-504. |
| [4] | Payeras MR, Cherubini K, Figueiredo MA, et al. Oral lichen planus: focus on etiopathogenesis [J]. Arch Oral Biol, 2013, 58(9):1057-1069. |
| [5] | Kurago ZB. Etiology and pathogenesis of oral lichen planus: an overview [J]. Oral Surg Oral Med Oral Pathol Oral Radiol, 2016, 122(1):72-80. |
| [6] | Lodi G, Scully C, Carrozzo M, et al. Current controversies in oral lichen planus: report of an international consensus meeting. Part 2. Clinical management and malignant transformation [J]. Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 2005, 100(2):164-178. |
| [7] | González-Moles MA, Ruiz-Ávila I, González-Ruiz L, et al. Malignant transformation risk of oral lichen planus: A systematic review and comprehensive meta-analysis [J]. Oral Oncol, 2019, 96:121-130. |
| [8] | García-Pola MJ, González-Álvarez J, Garcia-Martin JM, et al. Treatment of oral lichen planus. Systematic review and therapeutic guide [J]. Med Clin (Barc), 2017, 149(8):351-362. |
| [9] | Chiang CP, Chang YF, Wang YP, et al. Oral lichen planus: Differential diagnoses, serum autoantibodies, hematinic deficiencies, and management [J]. J Formos Med Assoc, 2018, 117(9):756-765. |
| [10] | Oray M, Abusamra K, Ebrahimiadib N, et al. Long-term side effects of glucocorticoids [J]. Expert Opin Drug Saf, 2016, 15(4):457-465. |
| [11] | Wang G, Wu J, Miao M, et al. Nocardia rubra cell-wall skeleton promotes CD4+T cell activation and drives Th1 immune response [J]. Int J Biol Macromol, 2017, 101:398-407. |
| [12] | Wang Y, Hu Y, Ma B, et al. Nocardia rubra cell wall skeleton accelerates cutaneous wound healing by enhancing macrophage activation and angiogenesis [J]. J Int Med Res, 2018, 46(6):2398-2409. |
| [13] | Meng Y, Sun J, Wang X, et al. The biological macromolecule Nocardia rubra cell-wall skeleton as an avenue for cell-based immunotherapy [J]. J Cell Physiol, 2019, 234(9):15342-15356. |
| [14] | Kato H, Inoue M, Yamamura Y, et al. Effect of recombinant human granulocyte colony-stimulating factor (rhG-CSF) on cytotoxi-city of PSK-induced peritoneal polymorphonuclear leukocytes (PMNs) [J]. Biotherapy, 1992, 5(3):177-186. |
| [15] | Ohara K, Hirano Y, Ishida H, et al. Possible involvement of lymphocyte activating factor (LAF) as an endogenous pyrogen in fever induced by the cell wall skeleton of Nocardia rubra (N-CWS) [J]. Chem Pharm Bull (Tokyo), 1990, 38(3):804-806. |
| [16] | 陶俊, 王颖, 叶波平, 等. 红色诺卡氏菌细胞壁骨架对小鼠急性肝损伤的保护作用 [J]. 中华肝脏病杂志, 2005, 13(8):618-619. |
| [17] | Meij EHVD, Waal IVD. Lack of clinicopathologic correlation in the diagnosis of oral lichen planus based on the presently available diagnostic criteria and suggestions for modifications [J]. J Oral Pathol Med, 2003, 32(9):507-512. |
| [18] | 刘青兰, 刘琳, 李留炀, 等. 曲安奈德口腔软膏治疗充血糜烂型口腔扁平苔藓的疗效及安全性观察 [J]. 实用口腔医学杂志, 2017, 33(4):536-540. |
| [19] | Gorouhi F, Solhpour A, Beitollahi JM, et al. Randomized trial of pimecrolimus cream versus triamcinolone acetonide paste in the treatment of oral lichen planus [J]. J Am Acad Dermatol, 2007, 57(5):806-813. |
| [20] | Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: Updated guidelines for reporting parallel group randomised trials [J]. BMJ, 2011, 9(8):672-677. |
| [21] | Park HK, Hurwitz S, Woo SB. Oral lichen planus: REU scoring system correlates with pain [J]. Oral Surg Oral Med Oral Pathol Oral Radiol, 2012, 114(1):75-82. |
| [22] | Chainani-Wu N, Silverman S Jr, Reingold A, et al. Validation of visual analogue scale, numeric rating scale, change in symptoms scale, and modified oral mucositis index for measurement of symptoms and signs of oral lichen planus [J]. Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 2006, 102(3):328. |
| [23] | Sampogna F, Derfeldt B, Axtelius B, et al. Comparison of patients’ and providers’ severity evaluation of oral mucosal conditions [J]. J Am Acad Dermatol, 2011, 65(1):69-76. |
| [24] | 周刚, 刘宏伟, 林梅, 等. 口腔扁平苔藓(萎缩型、糜烂型)疗效评价标准(试行) [J]. 中华口腔医学杂志, 2005, 40(2):92-93. |
| [25] | 黄悦勤. 临床流行病学 [M]. 北京: 人民卫生出版社, 2014. |
| [26] | Mauskar M. Erosive lichen planus [J]. Obstet Gynecol Clin North Am, 2017, 44(3):407-420. |
| [27] | Aghbari SMH, Abushouk AI, Attia A, et al. Malignant transformation of oral lichen planus and oral lichenoid lesions: A meta-analysis of 20 095 patient data [J]. Oral Oncol, 2017, 68:92-102. |
| [28] | Carrozzo M, Porter S, Mercadante V, et al. Oral lichen planus: A disease or a spectrum of tissue reactions? Types, causes, diagnostic algorhythms, prognosis, management strategies [J]. Periodontology 2000, 2019, 80(1):105-125. |
| [29] | 李春, 刘恩生, 穆荣, 等. 羟氯喹所致视网膜病变的文献分析 [J]. 药物不良反应杂志, 2010, 12(1):21-25. |
/
| 〈 |
|
〉 |
